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Background: Obstructive sleep apnea and hypopnea syndrome (OSAHS) is a disorder that causes clinical symptoms
(e.g. snoring, excessive daytime sleepiness and impaired concentration) that may increase the risk of traffic accidents,
cardiovascular disease, type 2 diabetes and reduce the quality of life. A recently developed device (Somnolter®) detects
apneas and hypopneas in a home setting, allowing to detect OSAHS in a more comfortable environment compared to
the gold standard polysomnography. The aim of our study was to investigate whether the Somnolter® is useful in
family practice to identify patients with OSAHS.
Methods: Questionnaires were offered to patients in five general practitioner (GP) practices.
Based on the questionnaire and body mass index, patients with an increased risk of OSAHS were contacted to collaborate
in the study. In this convenience sample, 18 patients were successfully tested with the Somnolter® measuring
SaO2, mandibular movements, body position, heart rate, nasal air flow and thoracic and abdominal breathing
movements. The Somnolter® automatically analyses the data and different parameters to detect OSAHS.
Afterwards, the data were manually revised by the researchers.
Results: Out of 365 subjects, 31 met the inclusion criteria and 18 were successfully tested at home. Sixteen out of
18 patients had an Apnea Hypopnea Index (AHI)≥ 5, ten of them had mild OSAHS, 3 were categorized as moderate
OSAHS and finally 3 matched the criteria of severe OSAHS.
Conclusion: The proposed case-finding strategy still needs optimization, but is considered helpful in selecting patients at
high risk of OSAHS. OSAHS was detected in 14 out of 18 patients tested with the Somnolter®. In the future the Somnolter®
might be a feasible alternative to diagnose OSAHS.
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Sleep apnea is a pathological phenomenon which can
result in clinical symptoms, e.g. daytime fatigue, exces-
sive sleepiness, impaired concentration, depression. The
combination of symptoms and proven breathing abnor-
malities during polysomnography (PSG) is historically
framed in more or less distinguished syndromes. The
obstructive sleep apnea syndrome (OSAS) is originally
described by Gulleminault in 1976 [1]. When not only
apneas but also hypopneas are taken into account, the
name changes into obstructive sleep apnea hypopnea
syndrome (OSAHS). Also central sleep apnea-hypopnea* Correspondence: jan.degryse@med.kuleuven.be
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unless otherwise stated.syndrome (CHAHS), Cheyne-stokes breathing syndrome
(CSBS) and sleep hypoventilation syndrome (SVHS) are
recognized as pathological entities. The upper airway re-
sistance syndrome (UARS) is a more controversial term
that covers the part of the spectrum without oxygen
desaturation.
Of these sleep related breathing disorders, OSAHS is
the most common worldwide [2]. Despite the high preva-
lence, 70-80% of patients with OSAHS remains undiag-
nosed [3-5]. Numerous studies show prevalence rates of
4% in men and 2% in women [6,7] while other large popu-
lation studies reveal increased apnea-hypopnea indexes
(AHI) in up to 26% of participants [6,8-10]. These preva-
lence rates differ substantially because of inadequate
syndrome definitions leading to difficulties to correctly
compare results. Also in children OSAHS is common.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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up to 5.7% of the screened pediatric population has
OSAHS [11]. Therefore, even children and adolescents
with a high risk of having OSAHS, should be screened.
Important studies concerning the prevalence of OSAHS
are mentioned in Additional file 1: Appendix 1.
In 1999 the American Academy of Sleep Medicine
(AASM) Task Force developed recommendations for
OSAHS syndrome definition and diagnostic measure-
ment techniques [12]. These diagnostic criteria were
established to minimalize the difficulties of comparing
study results, e.g. prevalence rates. Diagnostic criteria
are cited in Additional file 1: Appendix 2. The purview
and limitations of these criteria are further explained in
Additional file 1: Appendix 3.
It is crucial for health care professionals, especially
when working in primary care, to gain the necessary
knowledge about risk factors for OSAHS in order to
adequately identify high risk patients. Both modifiable
and non-modifiable risk factors associated with OSAHS
are summarized in Additional file 1: Appendix 4. From
all risk factors, excess body weight seems to be one of
the most important risk factors for OSAHS [5,13,14].
Therefore long-term weight reduction might be a helpful
factor in the conservative treatment of obstructive sleep
apnea.
OSAHS is also associated with a number of negative
consequences on health. Studies show an increased risk
of traffic accidents, arterial hypertension, stroke, depres-
sion, cardiovascular diseases and type 2 diabetes [15].
The associated morbidity and its strength of evidence is
described in Additional file 1: Appendix 5 [16-18]. Some
inconsistency about the association between OSAHS
and coronary artery disease, arrhythmias, heart failure,
type 2 diabetes and depression remains. On the otherFigure 1 Mandibular movements analysed by the JAWAC-sensors (redhand a remarkable independent association with arterial
hypertension, stroke, cardiovascular mortality and death
from all-causes is clearly proven. Some of the under-
lying pathophysiological mechanisms are described in
Additional file 1: Appendix 6.
The aim of this pilot study was to set up a case-finding
strategy to identify high risk patients in whom it could be
useful to screen for OSAHS as it is a highly prevalent dis-
order with possible dangerous sequelae and very effective
treatment options (education and continuous positive
airway pressure) [19]. In a selected number of high risk
patients, a recently developed device, the Somnolter®, was
then used to investigate whether obstructive sleep apnea
could be detected. The Somnolter® is proven by Cheliout-
Heraut et al. in 2011 to be a valuable alternative with a
similar sensitivity and specificity as an in-hospital PSG,
the current gold standard, for diagnosing sleep apnea syn-
drome [20,21]. Both PSG and the Somnolter® record the
traditional parameters essential for the diagnosis of sleep
apnea syndrome but only the Somnolter® additionally
records mandibular movements (Figure 1). These move-
ments represent the respiratory effort during sleep and
will reflect the number of apnea episodes which are very
important for the diagnosis of sleep apnea syndrome. The
mandibular movements also allow to assess the total
sleeping time. Together with the other features of the
device, the recording of mandibular movements make the
Somnolter® feasible to detect sleep apnea in a comfortable
environment, such as the patients home.
Methods
Sampling
In this convenience sample, patients were selected using
a questionnaire based on recent literature on OSAHS
and the Epworth Sleepiness Scale (ESS). During fivearrows).
Figure 2 The Somnolter Device. Somnolter®recording the
midsagittal jaw movements through sensors placed on the forehead
and the chin, arterial oxygen saturation, body position, nasal airflow
and thoracic movements. Adapted with permission from: http://
www.nomics.be/uploads/pdf/Somnolter_Leaflet_EN-615.pdf.
Cattrysse et al. BMC Research Notes 2014, 7:616 Page 3 of 9
http://www.biomedcentral.com/1756-0500/7/616consecutive workdays, Dutch and French brochures con-
taining a questionnaire were offered to patients in four
Flemish general practitioners (GP) practices and one
mixed Flemish and French speaking GPs practice. These
questionnaires asked for the patients name, date of
birth, sex, weight, height, an answer on three screening
questions and the ESS. The three screening questions
enclosed : 1) ‘Do you snore or did someone ever tell you
that you snore?’, 2) ‘Do you feel extremely tired at
daytime?’ and 3) ‘Do you experience difficulties to con-
centrate at daytime?’. In three practices, the brochures
were systematically handed out to all patients aged 25
and older. In the other two practices the brochures were
offered to the patients by placing them in the waiting
room. All brochures were collected in boxes presented
in the GPs practice. Nine opportunistic subjects, who
were not a patient at one of the GPs practices men-
tioned above, heard about the study through one of the
co-workers and offered to participate by filling out the
brochure as well. Their questionnaires were analyzed
together with the other questionnaires collected at the
GPs practices mentioned above.
Inclusion and exclusion criteria
In case two or more screening questions were answered
positively, the ESS score was ≥ 10 and the patient had a
BMI of ≥ 25, he or she met the predetermined inclusion
criteria and was qualified to participate in the second
part of the study. Acute interfering pathology, progres-
sive cognitive impairment and important use of drugs
with sleepiness, drowsiness or somnolence as known
side effects, were set as exclusion criteria. Patients who
had been taking low-dose sleep medication for several
years were not excluded.
Patient selection
Due to time limitations, only a limited number of
patients who met the inclusion criteria could be offered
to participate in the second part of the study, namely a
home measurement using the Somnolter®. Eligible
patients were contacted by phone to reassure they met
the inclusion criteria and to offer them a home measure-
ment to detect possible OSAHS. Patient files were ana-
lyzed and those patients with a higher risk for OSAHS
(high ESS score, high BMI, comorbidities such as Down
Syndrome, family members with sleep apnea,…) were
contacted first. Nineteen of them gave their consent for
the second part of the study.
Home monitoring
A couple of hours before the patient went to bed, the
device was attached to the patient by one of the co-workers
of this study during a home visit. During this visit a more
comprehensive personal history including risk factors,regular medication and family history, was taken (Add-
itional file 1: Appendix 7). Patients were allowed to take
their regular medications. The next morning, the device
was retrieved and the patients were offered a question-
naire to ascertain whether they had encountered any side
effects during the night (Additional file 1: Appendix 8).
Somnolter® device
Figure 2 is a representation of the Somnolter® attachment.
The Somnolter® device records the following parameters:
pulse-oximetry, body position, heart rate, nasal air flow
and chest and abdominal movements. These are the
traditional parameters measured during ambulatory sleep
monitoring. The device additionally records mandibular
movements: the Jaw Activity (Jawac) signal. Mandibular
movements are said to be an excellent marker of respira-
tory effort during sleep, which is an important parameter
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Furthermore, the recording of mandibular movements
and its dedicated signal processing, allows to accurately
assess the total sleeping time in a home setting [22]. This
in contrast to a PSG in a hospital setting, camera record-
ing is done to distinguish whether the patient is awake or
asleep.
Interpretation procedure
The interpretation of results was based on automatic
analysis of the Somnolter® and manual revision of the
research team. The research team for example focused
on the temporal relation of jaw movements and apneas/
desaturations, which was not automatically analyzed by
the Somnolter®. These movements (Figure 1), as mentioned
before, represent the respiratory effort during sleep as they
will show a period of increased amplitude and frequency
reflecting the typical gasping mandibular movements oc-
curring after an episode of apnea and desaturation. AASM
criteria were used to distinguish between mild, moderate
and severe OSAHS. Diagnosis of OSAHS was validated by
two independent specialists in the near future.
Approval
This study was approved by the Medical Ethics Committee
of the Catholic University Hospital Leuven. All patients
gave informed consent to the investigations. No physical or
emotional harm was done to participating patients and all
the data were processed and analyzed anonymously. There
was no financial reward for those participating in this
study.
Results
A total of 365 questionnaires were filled out by patients
consulting the co-operating GPs practices or by patients
who heard from the study by one of the co-workers. The
mean age of this population was 53.67 ± 14.57 years old.
The sex ratio (male/female) was 6/10. The mean ESS
score was 6.56 ± 4.56 on a total of 24 points. A hundred
and sixty-eight patients out of 365 responded positively
to only one of the screening questions, 65 patients
responded positively to two screening questions and 61
answered positively to all three questions (Figure 3). Of 127
patients with ≥ 2 positive screening questions, 66 patients
had an ESS < 10 and 61 patients had an ESS ≥ 10.
Between the 61 patients of the eligible population, 32
patients also met the other inclusion criteria (age ≥ 25
and BMI ≥ 25) for diagnostic evaluation with Somnolter®.
Seven of them were excluded based on the exclusion cri-
teria mentioned earlier in this article. Nineteen subjects
agreed to be tested by home-monitoring. Registration
with Somnolter® failed in one patient, resulting in a
study population of 18 patients.Patient characteristics of the study population are
summarized in Table 1. The mean age of the study
population was 53.06 years old and all of the patients
were of Caucasian ethnicity. The sex ratio was 1/1. Of the
18 patients studied, 10 were treated with antihypertensive
drugs. Five people had a history of a cardiovascular event,
i.e. coronary stenting, cerebrovascular accident, transient
ischemic attack, Lyme myocarditis and myocardial in-
farction. Eight subjects reported difficulties concentrating.
Three were smoking at the time of this study and 3 had
been smoking in the past. The average pack years of the
smokers was 25 years. Almost all of the patients con-
sumed alcohol on a regular basis, but there was no exces-
sive alcohol use in any of the patients. Six of the 9 female
patients were post-menopausal. Six patients had com-
plaints of chronic rhinitis and/or sinusitis. At the time of
examination, one person had a common cold.
There appeared to be a heavy family burden in the study
population. A family history of OSAHS, prior familial
cardiovascular events and type 2 diabetes was reported by
6, 10 and 11 patients respectively.
Table 2 summarizes the most important information
from the Somnolter® reports. The mean ESS in our study
population was 13.33 on a total of 24 points. No clear
correlation between ESS and OSAHS was found. Except
for one, all of the patients slept more than 5 hours. Two
patients had an AHI < 5; this means no OSAHS accord-
ing to the AASM criteria. Ten subjects had an AHI
between 5 and 15, corresponding to mild OSAHS. Three
patients had an AHI between 15 and 30, which is mod-
erate OSAHS. Three subjects showed an AHI of ≥ 30,
matching severe OSAHS.
Eight patients had an obstructive apnea index (OAI) ≤ 1
per hour, 6 had an OAI between 1 and 5 per hour, 1 per-
son had an OAI between 5 and 10 per hour and the other
3 participants had a severe rise in OAI of 10.7, 35.3 and
46.5 respectively.
Other measured parameters were respiratory related
arousal index (RERA I), respiratory disturbance index
(RDI), respiratory arousal index (RAI) and the cumulative
time below 90% oxygen saturation (SaO2 CT 90). Though
these parameters varied a lot between the different patients
as shown in Table 2, some form of association could still be
seen. In patients with a SaO2 CT90 ≥ 1 hour (ranging from
1h29 minutes to 4h18 minutes), AHI, OAI, RDI and RAI
increased equably with increasing SaO2 CT90 (Additional
file 1: Appendix 9). This trend was not seen for RERA I.
When SaO2 CT 90 was corrected for the total sleeping
time, an even stronger trend could be seen (Additional
file 1: Appendix 10).
Each patient was also questioned about the user
friendliness of the Somnolter®. Results are summarized
in Table 3. On average, the patients reported to have
slept well. Three patients had the subjective feeling that
Figure 3 Screening population algorithm.
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considered annoying during sleeping. Eight patients
reported that one of the sensors disconnected during
sleep. Most often the pulse-oximeter or the nasal can-
nula disconnected. This disconnection however had no
consequences on the final analysis. As every sensor has
an individual and unique import, there is only one im-
port gate a sensor can be plugged into and there is only
one way to connect them to the device so most of the
patients were capable of reconnecting the sensors them-
selves whitin a few minutes. In the two cases where a
sensor was disconnected for most of the time sleeping,
the software could still analyze the data with the help of
the multiple parameter recordings and the very effective
Jawac signal. As in PSG, the multiple parameters re-
corded during sleep, will allow the software to appoint
hypopnea and apnea events even when registration with
one of the sensors has failed.
Discussion
This pilot study revealed 11 new and 3 borderline cases of
OSAHS on a total of 18 patients successfully tested with
the Somnolter®. This suggests that the used case-findingstrategy and questionnaire could adequately detect high
risk patients. The implementation of the proposed strategy
in the GPs practice is easy and little time-consuming. The
three screening questions about snoring, daytime somno-
lence and difficulties to concentrate, can easily be embed-
ded in a general risk determination. In this study, only the
patients with ≥ 2 positive answers on the 3 screening ques-
tions were further questioned using the ESS. Further re-
search is needed to see if it is also useful for patients with
only 1 positive question to fill out the ESS. To determine
if this proposed case-finding strategy increases the pretest
probability in a statistically significant way, case control
studies will be needed. These results also support the
statement mentioned before, namely that a high percent-
age (up to 70-80%) of patients with OSAHS is undiag-
nosed in the general population. Some explanations are
suggested. At first, GPs rarely think of OSAHS as a pos-
sible explanation for persisting complaints of fatigue. If no
somatic explanation is found at first sight, the complaints
are often attributed to mental causes such as depression
or chronic fatigue syndrome. For instance, patient 15
received antidepressants from his GP to treat his daytime
somnolence and lack of energy. The Somnolter® showed
Table 1 Patients characteristics
Patients Sex Age
(y)
BMI
(kg/m2)
AHT CVD Memory /
Concentration
Current
smoker
Pack
years
Alcohol
(units/w)
Post-meno-
pausal
History of recurrent
sinusitis
Other important
diagnosis
Family risk
factors
1 F 57 25 No No Impaired No 0 2 Yes Yes / DM2
2 M 63 28 Treated Coronal
stents
Impaired No 18 13 / No HyperCh OSAHS
3 M 54 41 Treated AMI and
PAD
Normal Yes 35 14 / Yes COPD CV, DM2
4 F 48 40 Yes Myocarditis Impaired Yes 30 4 No No / OSAHS
5 F 47 25 Treated No Impaired No 0 2 Yes No / CV
6 F 56 27 No No Impaired No 0 3 Yes No / CV, DM2
7 M 38 31 No No Normal No 0 3 / Yes DM2 OSAHS
8 F 78 30 Treated No Normal No 0 1 Yes Yes Osteopor. DM2
9 M 50 33 No No Normal No 20 5 / Yes HyperCh CV, DM2
10 M 60 30 Treated CVA Impaired No 0 0 / No Epilepsy CV
11 M 48 26 No No Normal No 0 12 / No / CV, DM2
12 F 28 29 No No Normal No 0 1 No Yes / OSAHS
13 M 67 32 Treated AMI Impaired No 25 5 / No DM2 OSAHS
14 M 40 25 No No Normal No 0 0 / Yes asthma /
15 M 43 29 No No Normal Yes 23 0 / No Down S/ CV, DM2
16 F 78 25 Treated TIA Impaired No 0 0 Yes No CKD - TIA /
17 F 51 34 Treated No Normal No 0 4 No No / OSAHS
18 F 62 35 No No Normal No 0 2 Yes Yes HyperCh CV
‘BMI’: Body Mass Index – ‘AHT’: arterial hypertension – ‘CVD’: cardiovascular disease - ‘Pack Years’: years smoked equal to 1 pack of cigarettes a day. – ‘Alcohol (units/w): amount of alcoholic units consumed on average
in a week – ‘PAD’: Peripheral atherosclerotic disease – ‘CVA’: cerebrovascular accident – ‘COPD’: chronic obstructive pulmonary disease – ‘DM2”: Type 2 Diabetes mellitus – ‘EBV’: Epstein Barr virus – ‘AF’: Atrial fibrillation
– ‘CDK’: Chronic kidney disease – ‘TIA’: Transient ischemic attack – ‘MVI’: Mitral Valve Insufficiency – ‘AMI’: Acute Myocardial Infarction – ‘HyperCh”: hypercholesterolemia – ‘osteopor’: osteoporosis – ‘Down S/’:
Down Syndrome.
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Table 2 Results questionnaires and Sonmolter© analysis
Patients Questions answered
“positive”
ESS Total sleep time AHI OAI RERA I RDI RAI SaO2 CT90 Oximetry Minimum
02 saturation
Diagnosis
1 3 12 7:18:19 14,5 0,4 3,1 17,7 12,3 0:02 77% OSAHS (positional)
2 2 13 7:13:34 59,5 35,3 4,7 64,2 51,8 2:19 70% Severe OSAHS
3 2 14 4:36:17 15,9 4,3 19,5 35,4 22,2 3:25 65% Severe OSAHS
4 3 18 9:49:14 5,8 0,5 24,0 29,8 27,3 0:03 86% Borderline OSAHS
5 3 18 7:49:30 4,1 0,9 4,1 8,2 6,6 0:00 90% Normal pattern
6 3 16 7:06:09 7,5 1,3 6,8 14,2 12,0 0:03 86% Normal pattern
7 2 11 7:50:56 14,7 3,3 15,2 29,8 25,0 0:07 79% OSAHS
8 2 12 9:49:30 12,3 3,9 16,9 29,2 24,1 0:12 83% OSAHS
9 2 10 5:25:53 21,4 10,7 15,1 36,5 29,8 0:10 78% OSAHS
10 3 16 8:35:48 12,3 0,6 8,3 20,6 18,0 0:03 88% Borderline OSAHS
11 3 14 7:35:31 12,0 0,8 2,6 14,6 8,4 0:03 86% OSAHS
12 2 11 8:13:10 1,1 0,2 1,2 2,3 1,3 0:00:42 84% Normal pattern
13 2 12 8:16:43 37,7 6,6 13,9 51,6 41,8 1:29 80% Severe OSAHS
14 2 10 8:18:30 11,7 0 4,5 16,1 12,2 0:00 92% Borderline OSAHS
15 2 10 9:01:43 60,8 46,5 12,7 73,5 62,1 4:18 67% Severe OSAHS
16 3 18 9:56:27 12,7 2,9 11,3 23,9 20,2 0:02 84% OSAHS
17 2 10 8:46:15 7,3 0,6 6,8 14,1 10,6 0:04 87% Normal pattern
18 3 15 8:24:27 23,3 6,9 11,2 34,5 28,1 1:42 78% OSAHS
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his symptoms. On the other hand depression might also
be a consequence of OSAHS [17], as stated before.
Secondly, when not handed out directly and systematically
to patients, fewer brochures were filled out. This might
reflect some kind of threshold for the patients to consult
their GP about snoring, excessive daytime sleepiness or
difficulties to concentrate during the day. This study
specifically asked for these symptoms through 3 screening
questions. A final explanation for this high number of un-
detected OSAHS is the fact that in-hospital PSG appears
to discourage patients. In the future the Somnolter® might
be a feasible alternative for the current PSG in the
hospital, possibly resulting in a higher number of OSAHS
diagnosis. When the diagnosis of OSAHS is confirmed,
patients would only need one admission to test and regu-
late the pressure of the CPAP-device. By reducing theTable 3 Patients’ experience
Patient experience Avg. score
Have you slept well? 2.7/4
How user friendly is the device? 3.0/4
Have you experienced the Somnolter® as disturbing? 1.6/4
Technical problems No
Loosened sensors 8
Score system : 0: not at all, 1: little, 2: neutral, 3: quite,
4: very muchneed for admission, waiting times for overnight PSG as
well as health care costs can be reduced.
Besides the 14 new diagnoses of OSAHS, other inter-
esting data regarding the sleep quality of patients were
analyzed by the Somnolter®. This allowed the authors to
draw supplementary conclusions. First, for some patients
the authors assigned another degree of OSAHS than
would be given by the AASM. Patient 1 for example
would normally be diagnosed as having mild OSAHS,
but because of a very low OAI (0.4/h) and a SaO2 CT90
of only 2 minutes, both related to supine position, she
was finally diagnosed with positional OSAHS. Although
an AHI of only 15.9/h, patient 3 was considered to have
severe instead of moderate OSAHS and this because of
long and deep desaturations (minimum SaO2 of 65%)
and a SaO2 CT90 of more than 3 hours. These 2 cases
indicate that besides AHI other parameters such as OAI,
body position, SaO2 CT90, maximum desaturation etc.
should be considered when assigning the degree of
OSAHS.
Secondly, the Somnolter® allows to distinguish the
more severe cases of OSAHS and to make a suggestion
towards an appropriate treatment. In patient 15 the
SaO2 CT90 was no less than 4 hours and 18 minutes
with a minimum SaO2 of 67%. This patient for example
has very severe OSAHS and should undoubtedly be
referred for further treatment. It is remarkable that
this patient, the most severe case of OSAHS in this
study population, is a patient with Down syndrome. As
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creases the risk of OSAHS [23]. On the other hand, in
patient 1 the apneas were related to supine position.
Taking measures to prevent this patient from sleeping in
supine position might be sufficient to minimalize the ap-
neas and deep desaturations and to decrease symptoms.
Finally, in patients with a SaO2 CT90 ≥ 1 hour (ranging
from 1h29 minutes to 4h18 minutes), AHI, OAI, RDI and
RAI increased equably with increasing SaO2 CT90. When
SaO2 CT 90 was corrected for the total sleeping, an even
stronger trend could be seen. Further research is needed
to establish a significant correlation.
The Somnolter® is a new generation device since the
Jawac sensors analyze jaw movements. The Jawac sen-
sors are a powerful tool giving an image of a persons’
snoring pattern as well as gasping movements during
sleep. Figure 1 shows gasping movements typically
appearing after a period of apnea and desaturation, and
followed by a slow increase of SaO2. In the future, fewer
sensors might be sufficient to adequately diagnose
OSAHS. For instance the Jawac sensor to detect gasping
combined with a pulse oxygen meter to detect desatura-
tions. Devices measuring only these two parameters are
already developed but further research is needed to con-
firm them as an adequate diagnostic tool.
It is important to stress that the questionnaire used in
this study cannot replace a thorough history taking. For
example, one of the patients was in a mourning phase
which could cause her troubled sleep and explain her
complaints of fatigue. This was only known after testing
with the Somnolter®. Another patient also reported, after
testing, that her fatigue could possibly be explained by
her recent motherhood. The used questionnaire did not
pick up these causes of fatigue. Therefore, an extra ques-
tion might need to be added to the questionnaire. For
example: ‘Do you have any idea why you are extremely
tired?’.
Limitations
The authors are well aware of the limitations of this pilot
study. In 3 of the 5 general practices, the brochure could
not be distributed in a systematic way. As a conse-
quence, in these general practices only prior interested
individuals filled out the document, resulting in a pos-
sible selection bias. In two GPs practices, the brochures
and questionnaires were handed out systematically by a
secretary, with very high response rates. Because of this
variable approach, the data cannot be considered to be
of epidemiologic value. Another limitation of the bro-
chures was an incomplete or incorrect completion by
the patient. Because of the short time period during
which this pilot study took place, in addition to having
only one Somnolter®-device available, a limited number
of patients could be tested.Conclusion
This pilot study set up a case-finding strategy to identify
high risk patients in whom it could be useful to screen
for OSAHS. Although the proposed strategy still needs
to be optimized, the authors concluded that their strategy
could definitely be helpful in selecting high risk patients.
They detected OSAHS in 14 out of 18 patients tested with
the Somnolter®, suggesting a high percentage of undiag-
nosed OSAHS in the general population.
In the future the Somnolter®, already proven to have a
similar sensitivity and specificity as the gold standard in-
hospital polysomnography, might be a feasible alternative
to diagnose OSAHS. Patients experience the Somnolter®
as less discouraging than polysomnography since it is
more comfortable and can be done in a home-setting.
Additional file
Additional file 1: Appendix 1-10 [24-27].
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